(Reuters) - NEW YORK, July 24 - Barr Pharmaceuticals Inc. said on Tuesday it is challenging the patent for Schering-Plough Corp.'s brain-cancer drug Temodar in an effort to bring generic versions to the market.
Schering-Plough and the patent owner, Cancer Research Technology, sued last Friday in U.S. federal court in Delaware to prevent the generic drugmaker from selling the product, Barr said.
Read more at Reuters.com Government Filings News
Schering-Plough and the patent owner, Cancer Research Technology, sued last Friday in U.S. federal court in Delaware to prevent the generic drugmaker from selling the product, Barr said.
Read more at Reuters.com Government Filings News
No comments:
Post a Comment